Emotional disorders (depressive and anxiety disorders).
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive the Unified Protocol (UP) transdiagnostic treatment protocol based on Barlow et al.’s therapist guide (2018) in the form of 12 w
Sessions 3–4: Increasing emotional awareness, self-monitoring training, and identifying emotional patterns
Sessions 5–6: Flexible cognitive appraisal, cognitive restructuring, and challenging negative thoughts
Sessions 7–9: Mindful emotional exposure and prevention of emotion-based avoidance behaviors
Sessions 10–11: Tolerance of physical discomfort, increasing behavioral activation, and strengthening adaptive behaviors
Session 12: Reviewing skills, relapse prevention, and planning for continued skills practice. Intervention 2: Control group: In treatment-as-usual Group (Psychoeducation), participants will have acces
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Diagnosis of at least one emotional disorder (including depressive disorders and anxiety spectrum disorders based on SCID-I). Age range between 18 and 55 years old. Ability to read and write. Willingness to participate in the research based on the terms of the written informed consent.
Exclusion criteria
Exclusion criteria: Use of psychiatric medication, or having a stable dosage of medication for at least 3 months prior to enrollment. Diagnosis of bipolar spectrum disorders, psychotic spectrum disorders, or schizotypal personality disorder (based on SCID-II). History of substance or alcohol abuse in the last 3 months. Receipt of Unified Protocol (UP) and/or CBT for emotional disorders in the last year, for more than 4 sessions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of depressive symptoms. Timepoint: Measurement of the severity of depressive symptoms at the beginning of the study (before the intervention), after the completion of the intervention, and 3 months after the completion of the intervention. Method of measurement: Depression Anxiety Stress Scales (DASS-21).;Severity of anxiety symptoms. Timepoint: Measurement of the severity of anxiety symptoms at the beginning of the study (before the intervention), after the completion of the intervention, and 3 months after the completion of the intervention. Method of measurement: Depression Anxiety Stress Scales (DASS-21). | — |
Secondary
| Measure | Time frame |
|---|---|
| Attentional Control. Timepoint: Measurement of the attentional control score at the beginning of the study (before the intervention), after the completion of the intervention, and 3 months after the completion of the intervention. Method of measurement: Attentional Control Scale (ACS).;Interoceptive Awareness. Timepoint: Measurement of the interoceptive awareness score at the beginning of the study (before the intervention), after the completion of the intervention, and 3 months after the completion of the intervention. Method of measurement: Multidimensional Assessment of Interoceptive Awareness (MAIA).;Emotional Self-Efficacy. Timepoint: Measurement of the emotional self-efficacy score at the beginning of the study (before the intervention), after the completion of the intervention, and 3 months after the completion of the intervention. Method of measurement: Emotional Self-Efficacy Scale (ESES).;Neuroticism. Timepoint: Measurement of the neuroticism score at the beginning of the study (before the intervention), after the completion of the intervention, and 3 months after the completion of the intervention. Method of measurement: NEO Five Factor Inventory-Neuroticism subscale (NEO-FFI-N). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Banafshe Mohajerin
Shahid Beheshti University of Medical Sciences
Outcome results
None listed